Policy & Regulation
BioNTech and Fosun commence Phase II trial of BioNTech's COVID-19 vaccine in China
25 November 2020 -

German biotechnology company BioNTech SE and Chinese pharmaceutical company Shanghai Fosun Pharmaceutical (Fosun) will launch a Phase II clinical trial of BioNTech's experimental COVID-19 vaccine in China, Reuters news agency reported on Wednesday.

In a statement, BioNTech and Fosun said that this vaccine, known as BNT162b2, will be tested on volunteers at the Jiangsu Provincial Centre for Disease Control and Prevention to assess safety and immunogenicity, eyeing future approval in China.

In addition, BioNTech is working with US pharmaceutical company Pfizer Inc on the vaccine.

The companies had said last week they were hoping to win approval in the US and Europe this year, after trial results showed the compound had a 95% efficacy rate and caused no serious side effects.

Login
Username:

Password: